JP6368383B2 - 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド - Google Patents

鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド Download PDF

Info

Publication number
JP6368383B2
JP6368383B2 JP2016575499A JP2016575499A JP6368383B2 JP 6368383 B2 JP6368383 B2 JP 6368383B2 JP 2016575499 A JP2016575499 A JP 2016575499A JP 2016575499 A JP2016575499 A JP 2016575499A JP 6368383 B2 JP6368383 B2 JP 6368383B2
Authority
JP
Japan
Prior art keywords
dihydro
benzoxazin
oxo
carbonyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016575499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522300A (ja
JP2017522300A5 (enExample
Inventor
ギャビン・オマホニー
ミーケル・コッセンヤンス
カール・エドマン
ヨハン・カヤヌス
カール・アンデシュ・ホグナー
フィリップ・コーンウォール
アンドリュー・ターナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2017522300A publication Critical patent/JP2017522300A/ja
Publication of JP2017522300A5 publication Critical patent/JP2017522300A5/ja
Application granted granted Critical
Publication of JP6368383B2 publication Critical patent/JP6368383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2016575499A 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド Active JP6368383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
US62/018,790 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2017522300A JP2017522300A (ja) 2017-08-10
JP2017522300A5 JP2017522300A5 (enExample) 2018-07-19
JP6368383B2 true JP6368383B2 (ja) 2018-08-01

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575499A Active JP6368383B2 (ja) 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド

Country Status (26)

Country Link
US (2) US10017502B2 (enExample)
EP (1) EP3160948B1 (enExample)
JP (1) JP6368383B2 (enExample)
KR (1) KR102012222B1 (enExample)
CN (1) CN106536491B (enExample)
AR (1) AR101036A1 (enExample)
AU (1) AU2015282450C1 (enExample)
CA (1) CA2953655C (enExample)
CY (1) CY1121596T1 (enExample)
DK (1) DK3160948T3 (enExample)
EA (1) EA029518B1 (enExample)
ES (1) ES2707726T3 (enExample)
HR (1) HRP20190147T1 (enExample)
HU (1) HUE042370T2 (enExample)
LT (1) LT3160948T (enExample)
ME (1) ME03316B (enExample)
MX (1) MX367404B (enExample)
PL (1) PL3160948T3 (enExample)
PT (1) PT3160948T (enExample)
RS (1) RS58274B1 (enExample)
SI (1) SI3160948T1 (enExample)
SM (1) SMT201900039T1 (enExample)
TR (1) TR201900659T4 (enExample)
TW (1) TWI677498B (enExample)
UY (1) UY36195A (enExample)
WO (1) WO2016001631A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03316B (me) * 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
JOP20210009A1 (ar) 2018-07-19 2021-01-12 Astrazeneca Ab طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
BR112020008705A2 (pt) * 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
JP2023536009A (ja) 2020-07-27 2023-08-23 アストラゼネカ・アクチエボラーグ ダパグリフロジンによる慢性腎疾患の処置方法
BR112023025793A2 (pt) * 2021-06-15 2024-02-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composto de fórmula (ii), um estereoisômero deste ou um sal farmaceuticamente aceitável deste, composição farmacêutica e uso do composto
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
US20250381145A1 (en) 2022-09-01 2025-12-18 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
WO2024125591A1 (zh) * 2022-12-15 2024-06-20 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085868A1 (en) * 2001-04-23 2002-10-31 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
WO2004056820A1 (en) * 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
CN101018552A (zh) * 2004-07-14 2007-08-15 利亘制药公司 细胞内受体调节剂化合物和方法
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
TW200732331A (en) 2005-12-28 2007-09-01 Takeda Pharmaceuticals Co Fused heterocyclic compound and use thereof
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
ES2375877T3 (es) 2006-10-31 2012-03-07 Pfizer Products Inc. Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides.
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
US8063090B2 (en) 2007-03-23 2011-11-22 Merck Sharp & Dohme Corp. Mineralocorticoid receptor modulators
TWI444185B (zh) 2007-04-09 2014-07-11 Daiichi Sankyo Co Ltd 吡咯衍生物之阻轉異構物
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP2011524896A (ja) * 2008-06-18 2011-09-08 アストラゼネカ・アクチエボラーグ 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
CA2756250A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
WO2011141846A2 (en) 2010-05-11 2011-11-17 Koninklijke Philips Electronics N.V. Lighting module
EP2569310A1 (en) 2010-05-11 2013-03-20 Pfizer Inc Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
EP2638012A1 (en) 2010-11-10 2013-09-18 Boehringer Ingelheim International GmbH Pyridyl ureas as mineralocorticoid receptor antagonists
ME03316B (me) * 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora

Also Published As

Publication number Publication date
HUE042370T2 (hu) 2019-06-28
ES2707726T3 (es) 2019-04-04
SI3160948T1 (sl) 2020-06-30
AU2015282450B2 (en) 2018-05-10
MX2017000183A (es) 2017-04-25
JP2017522300A (ja) 2017-08-10
LT3160948T (lt) 2019-02-11
TWI677498B (zh) 2019-11-21
CN106536491B (zh) 2018-12-18
CN106536491A (zh) 2017-03-22
RS58274B1 (sr) 2019-03-29
US20150376170A1 (en) 2015-12-31
ME03316B (me) 2019-10-20
MX367404B (es) 2019-08-20
WO2016001631A1 (en) 2016-01-07
KR20170021883A (ko) 2017-02-28
US9394291B2 (en) 2016-07-19
EA029518B1 (ru) 2018-04-30
EP3160948B1 (en) 2018-10-24
CY1121596T1 (el) 2020-05-29
AR101036A1 (es) 2016-11-16
CA2953655A1 (en) 2016-01-07
US20170217945A1 (en) 2017-08-03
AU2015282450C1 (en) 2018-09-20
AU2015282450A1 (en) 2017-02-02
PT3160948T (pt) 2019-02-01
PL3160948T3 (pl) 2019-04-30
EA201790046A1 (ru) 2017-08-31
UY36195A (es) 2016-01-08
EP3160948A1 (en) 2017-05-03
US10017502B2 (en) 2018-07-10
TR201900659T4 (tr) 2019-02-21
KR102012222B1 (ko) 2019-10-21
SMT201900039T1 (it) 2019-02-28
CA2953655C (en) 2020-05-12
DK3160948T3 (en) 2019-02-18
TW201613909A (en) 2016-04-16
HRP20190147T1 (hr) 2019-03-22

Similar Documents

Publication Publication Date Title
KR102012222B1 (ko) 무기질코르티코이드 수용체 조절제로서의 벤족사지논 아미드
JP5564036B2 (ja) ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体
JP6466433B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
CZ283680B6 (cs) Nové azaheterocyklylmethyl-chromany
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用
EA024933B1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
TW202222770A (zh) 苄胺或苄醇衍生物及其用途
KR102720397B1 (ko) 질환 치료용 복소환식 화합물
CN105073724A (zh) 作为钾离子通道抑制剂的2,3-二氮杂萘类化合物
WO2023166303A1 (en) Acrylamide compounds
CA2841897A1 (en) Novel compound having parp inhibitory activity
TW202110845A (zh) 三環化合物
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
CZ281714B6 (cs) Piperidylmethylsubstituované deriváty chromanu
HK1237338A1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
HK1237338B (en) Benzoxazinone amides as mineralocorticoid receptor modulators
EP3204385A1 (en) Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
KR19990028550A (ko) 편두통 치료용의 1,6-이치환된 이소크로만

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180306

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180306

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180614

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180619

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180706

R150 Certificate of patent or registration of utility model

Ref document number: 6368383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250